Introduction {#j_bjmg-2018-0010_s_001}
============

Depression is a major cause of disease and disability. It consists of several symptoms, such as depressed mood, loss of interest or pleasure, decreased energy, feelings of guilt or low self-worth, disturbed sleep or appetite, and poor concentration. One-third of all people seeking psychiatric help are depressed; in more economically developed countries, one in five people will be depressed at least once in his/her life, and in poorer ones, this ratio is much worse.

Major depression usually strikes without a a discernible triggering event. This can be confusing and frustrating for both the person affected and his/her surroundings. People expect their illnesses to have clear causes, but many serious diseases, such as cancer, usually have none. Major depression is indeed a serious disease that often causes despair and hopelessness so profound that the person loses all interest in life, becomes incapable of feeling pleasure, and may be unable to get out of bed or eat for days at a time. The total annual cost of depression in Europe is about 253 Euro per inhabitant \[[@j_bjmg-2018-0010_ref_001]\].

Genetic susceptibility to major depressive disorder (MDD) is a field of study that has baffled many researchers; while it has shown great promise, it has actually yielded very few tangible results. Major depressive disorder has long been known to be moderately heritable. Twin studies have repeatedly shown the heritability of major depression to be about 37.0-38.0% \[[@j_bjmg-2018-0010_ref_002], [@j_bjmg-2018-0010_ref_003]\]. Different approaches to studying the genetics of MDD have so far been consistent only in their inconsistency; linkage studies, candidate gene approaches, studies of gene-environment interaction, and more recent genome-wide association studies (GWAS) have failed to give significant or reproducible results \[[@j_bjmg-2018-0010_ref_004], [@j_bjmg-2018-0010_ref_005]\]. Genome-wide association studies in particular have shattered hopes of finding significant common risk variants. Previously detected associations with genes such as those in the monoamine synthesis pathway have not been replicated in GWAS and no new, clear-cut candidates significantly associated with MDD have been discovered \[[@j_bjmg-2018-0010_ref_006], [@j_bjmg-2018-0010_ref_007]\]. These results are in stark contrast to results for other complex diseases such as diabetes, Crohn's disease, and rheumatoid arthritis, where GWAS have been considerably more successful in identifying potentially interesting loci \[[@j_bjmg-2018-0010_ref_008], [@j_bjmg-2018-0010_ref_009], [@j_bjmg-2018-0010_ref_010]\]. Researchers are now trying to find novel approaches in their quest for the missing heritability of MDD \[[@j_bjmg-2018-0010_ref_011]\].

Many reviewers agree that the aforementioned failure of GWAS could be due to the fact they were underpowered \[[@j_bjmg-2018-0010_ref_012]\]. A great number of different loci might play a role in determining a person's predisposition to develop MDD, but if that is indeed the case, the effect of each contributing variant could be exceedingly small. It has been estimated that sample sizes in excess of 50,000 might be needed for variants with genome-wide significance to be discovered \[[@j_bjmg-2018-0010_ref_011]\].

A possible approach that might enable researchers to lower the necessary number of participants in future studies would be to concentrate on the various subtypes of depressive disorders, as there is evidence MDD is a genetically heterogeneous disorder \[[@j_bjmg-2018-0010_ref_013]\]. Depression is more heritable in women and is associated with different genetic variants in both sexes \[[@j_bjmg-2018-0010_ref_014], [@j_bjmg-2018-0010_ref_015]\]. Studying patients with early onset disease, choosing patients with more severe forms of the disease and a higher recurrence rate, as well as focusing on various clinical subtypes, could also help distinguish between different genetic influences. It is also important to acknowledge that there is a considerable overlap between MDD and other psychiatric disorders such as bipolar disorder and generalized anxiety disorder (GAD). Some studies show that the genetic factors underlying both MDD and GAD are essentially the same \[[@j_bjmg-2018-0010_ref_016], [@j_bjmg-2018-0010_ref_017], [@j_bjmg-2018-0010_ref_018], [@j_bjmg-2018-0010_ref_019]\].

Another approach to subdividing patients with MDD that has occasionally been used in the past, is to enquire about their family history of depression. A positive family history is the most important risk factor for developing a depressive disorder and is often found in patients with more severe and recurrent disease and an earlier age of onset \[[@j_bjmg-2018-0010_ref_020], [@j_bjmg-2018-0010_ref_021]\]. Linkage studies performed in families with several affected members have shown that many different loci could be associated with the familial form of the disease \[[@j_bjmg-2018-0010_ref_022], [@j_bjmg-2018-0010_ref_023]\]. Estimates of single nucleotide polymorphism (SNP) heritability performed so far seem to indicate that more than 50.0% of MDD heritability is due to common variants \[[@j_bjmg-2018-0010_ref_024]\], but the possibility that rare variants of great effect also account for some MDD heritability cannot be excluded. It is therefore possible that both combinations of common risk variants and specific rare variants are at play in familial cases.

Based on these findings, our study aimed to explore the connection between the family history of depression and the presence of common genetic risk factors for MDD. First, we set out to determine the allele and genotype distributions for the extensively studied SLC6A4, COMT and PCLO polymorphisms in Slovene patients with MDD and to compare them to healthy controls. We then tried to detect any differences in the prevalence of these putative genetic risk variants in MDD patients with a positive family history of depressive disorder compared to sporadic cases with no affected relatives.

Materials and methods {#j_bjmg-2018-0010_s_002}
=====================

**Subjects**. Of the 133 patients participating in this study, most were recruited *via* the Outpatient Psychiatry Centre of the University Psychiatric Hospital in Ljubljana, Slovenia. All had been previously diagnosed with either MDD, or in rare cases GAD, by an experienced psychiatrist, in accordance with the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, 1994; American Psychiatric Association) classification system criteria. A small number of patients was recruited by their general practitioners; they had all been diagnosed as having MDD in the past by a psychiatrist. No patients with a history of schizophrenic, schizoaffective or bipolar disorder or a diagnosis of personality disorder were included in our study. Patients with MDD showing psychotic symptoms were likewise excluded from further analysis.

A total of 279 healthy controls were enrolled in our study while undergoing screening examinations at various occupational medicine departments across Slovenia. Only healthy volunteers with no personal or family history of depression were recruited.

All participants were required to fill in a structured questionnaire enquiring about their general health and habits and about the family history of neuropsychiatric disorders in their first-, second-and third-degree relatives. They also completed the Zung Self-Rating Depression Scale (SDS). No controls that scored 45 or more on the SDS were included in our study.

Blood samples and, in a small number of MDD patients, buccal swabs were obtained from all participants. All patients and controls were of Caucasian origin. They all signed written informed consent forms. The study was conducted in accordance with the Declaration of Helsinki (1964) and was approved by the Slovenian National Ethics Committee.

**Genotyping**. Genomic DNA was extracted from blood samples and buccal swabs using standard protocols. Genotyping of the *COMT* rs4680 and *PCLO* rs2522833 was performed using a real-time polymerase chain reaction (RT-PCR) method on a 7000 Sequenced Detection System (Applied Biosystems, Foster City, CA, USA). KASPar (LGC Ltd., Teddington, Middlesex, UK) SNP genotyping chemistry was utilized according to the manufacturer's protocols. Polymerase chain reaction was carried out in a 10 μL final volume containing 5 μL of a DNA sample, 5 μL of Reaction Mix 2 × and 0.14 μL of Assay Mix. After initial denaturation at 94 °C for 15 min., 20 denaturation cycles (94 °C for 10 seconds, 57 °C for 5 seconds, 72 °C for 20 seconds) were performed, followed by the final extension step of 40 seconds at 72 °C. The allele discrimination analysis was carried out using SDS Software Version 1.2 (Applied Biosystems) \[[@j_bjmg-2018-0010_ref_025]\].

Genotyping of the 5-HTTLPR variant was performed in accordance with procedures previously described in the literature \[[@j_bjmg-2018-0010_ref_026]\]. The *5-HTT* gene regulatory region was amplified by PCR with the following primers: 5'-GGC GTT GCC GCT CTG AAT GC-3' and 5 '-GAG GGA CTG AGCT GGA CAA CCA C-3'. Polymerase chain reaction was performed in a 10 μL reaction mixture containing 1 μL of genomic DNA, 0.3 μL of each primer, 0.2 μL of PCR Nucleotide Mix, 2 μL of GoTaq® Flexi Buffer, 0.8 μL of 25 mM MgCl2 solution, 0.1 μL of GoTaq® DNA Polymerase and 5.3 μL of H~2~O. Denaturation was performed at 94 °C for 2 min. and was followed by 30 cycles of amplification (98 °C for 10 seconds, 63 °C for 30 seconds and 68 °C for 30 seconds). The PCR products were separated using electrophoresis in a 3.0% agarose gel and visualized by UV after SYBR®Safe staining. A 484 bp band was observed for the short (S) allele, and a 528 bp band for the long (L) allele; heterozygous samples showed both alleles.

**Statistical Analyses**. Genotype distributions were tested for adherence to the Hardy-Weinberg disequilibrium using the χ^2^ distribution test. The χ^2^ test was also used to analyze the significance of associations between genotype and allele frequencies and MDD. Patients with MDD were compared to a control group consisting of healthy volunteers. In addition, a group of patients with a positive family history of depressive disorders was compared to patients with no family history of depression, and both groups of patients were separately compared to healthy controls. Analyses were performed using *R* statistical language (*R* 3.1.1 for Windows; [https://cran.r-project.org/bin/windows/base/old/3.3.1)](http://https://cran.r-project.org/bin/windows/base/old/3.3.1) A nominal level of significance *p* = 0.05 was regarded as significant and corrected according to Benjamini-Hochberg when multiple tests were performed.

Results {#j_bjmg-2018-0010_s_003}
=======

Genotype distributions for tested SNPs in control samples adhered to the Hardy-Weinberg equilibrium. No significant difference in distribution was detected when comparing the MDD cases and healthy controls for any of the variants tested. There were no significant differences using the dominant, recessive or codominant model (data not shown). Genotype and allele distributions for the three tested variants in 133 patients with MDD and 279 healthy controls are shown in [Table 1](#j_bjmg-2018-0010_tab_001){ref-type="table"}.

###### 

Genotype and allele distributions of the *PCLO* rs2522833, *COMT* rs4680 and *SLC6A4* 5-HTTLPR polymorphic variants in major depressive disorder/generalized anxiety disorder patients and controls.

                          MDD/GAD Patients (*n* = 133)   Controls (*n* = 279)   *p* Value
  ----------------------- ------------------------------ ---------------------- -----------
  *PCLO* rs2522833                                                              
  Genotype frequencies:   *n* (%)                        *n* (%)                
   AA                     59 (0.44)                      122 (0.44)             
   AC                     58 (0.43)                      112 (0.40)             0.567
   CC                     16 (0.12)                      44 (0.16)              
  Alleles:                                                                      
   A                      176 (0.66)                     356 (0.64)             0.549
   C                      90 (0.34)                      176 (0.36)             
  *COMT* rs4680                                                                 
  Genotype frequencies:   *n* (%)                        *n* (%)                
   GG                     26 (0.21)                      67 (0.24)              
   GA                     73 (0.56)                      154 (0.56)             0.51
   AA                     31 (0.23)                      55 (0.20)              
  Alleles:                                                                      
   G                      125 (0.48)                     288 (0.52)             
   A                      135 (0.52)                     264 (0.48)             0.276
  *SLC6A4* 50HTTLPR                                                             
  Genotype frequencies:   *n* (%)                        *n* (%)                
   LL                     44 (0.34)                      100 (0.36)             
   LS                     70 (0.52)                      131 (0.48)             0.614
   SS                     19 (0.14)                      45 (0.16)              
  Alleles:                                                                      
   L                      158 (0.59)                     331 (0.60)             
   S                      108 (0.41)                     221 (0.40)             0.877

MDD: major depressive disorder; GAD: generalized anxiety disorder.

A comparison of the genotype and allele frequency distributions was also performed between the group of MDD patients with a positive family history for depression and patients with no such family history. A significant difference in genotype and allele frequencies was detected between the two groups of patients for the *PCLO* rs2522833 polymorphism. The association remained significant even after correction for multiple testing; no other association reached the threshold of statistical significance. Both patients with a positive family history and those with a negative family history were also compared to healthy controls. A significant difference in the allele and genotype frequencies was detected between the familial cases and controls, again for the *PCLO* rs2522833 polymorphism. The results are shown in [Table 2](#j_bjmg-2018-0010_tab_002){ref-type="table"}.

###### 

Genotype and allele distribution of the *PCLO* rs2522833, *COMT* rs4680 and *SLC6A4* 5-HTTLPR polymorphic variants in major depressive disorder/generalized anxiety disorder patients with a positive or negative family history for depressive disorders.

                          Positive Family History (*n* = 40)   *p* Value: Positive Family History *vs*. Controls   Negative Family History (*n* = 93)   *p* Value: Negative Family History *vs*. Controls   *p* Value: Positive *vs*. Negative Family History
  ----------------------- ------------------------------------ --------------------------------------------------- ------------------------------------ --------------------------------------------------- ---------------------------------------------------
  *PCLO* rs2522833                                                                                                                                                                                          
  Genotype frequencies:   *n* (%)                                                                                  *n* (%)                                                                                  
   AA                     26 (0.65)                                                                                33 (0.36)                                                                                
   AC                     14 (0.35)                            **0.007**                                           44 (0.47)                            0.354                                               **0.001**
   CC                     0 (0.00)                                                                                 16 (0.17)                                                                                
  Alleles:                                                                                                                                                                                                  
   A                      66 (0.82)                                                                                110 (0.59)                                                                               
   C                      14 (0.18)                            **0.001**                                           76 (0.41)                            0.232                                               **0.000**
  *COMT* rs4680                                                                                                                                                                                             
  Genotype frequencies:   *n* (%)                                                                                  *n* (%)                                                                                  
   GG                     10 (0.25)                                                                                16 (0.18)                                                                                
   GA                     18 (0.45)                            0.297                                               55 (0.61)                            0.439                                               0.232
   AA                     12 (0.30)                                                                                19 (0.21)                                                                                
  Alleles:                                                                                                                                                                                                  
   G                      38 (0.48)                                                                                87 (0.48)                                                                                
   A                      42 (0.52)                            0.434                                               93 (0.52)                            0.371                                               0.901
  *SLC6A4* 50HTTLPR                                                                                                                                                                                         
  Genotype frequencies:   *n* (%)                                                                                  *n* (%)                                                                                  
   LL                     18 (0.45)                                                                                26 (0.28)                                                                                
   LS                     18 (0.45)                            0.436                                               52 (0.56)                            0.302                                               0.148
   SS                     4 (0.10)                                                                                 15 (0.16)                                                                                
  Alleles:                                                                                                                                                                                                  
   L                      54 (0.67)                                                                                104 (0.56)                                                                               
   S                      26 (0.33)                            0.197                                               82 (0.44)                            0.332                                               0.078

MDD: major depressive disorder; GAD: generalized anxiety disorder.

Discussion {#j_bjmg-2018-0010_s_004}
==========

The polymorphic variants included in our analyses have all been thoroughly studied in connection to psychiatric disease. The common Val158Met polymorphism in the *COMT* gene (due to a G\>A transition) has been the subject of several association studies performed in different populations and often with conflicting results. Whereas some studies have detected an association between the low activity methionine allele and depression, others have yielded opposite, or, more often, negative results \[[@j_bjmg-2018-0010_ref_027], [@j_bjmg-2018-0010_ref_028]\]. The 5-HTTLPR promoter repeat variant of the *SLC6A4* gene is perhaps the most widely studied of all the common variants that were investigated in MDD using the candidate gene approach. Two variants are usually reported in humans, namely the short (S) and long (L) allele, although the repeat region is complex and can be subdivided into several allelic variants. The S allele has been repeatedly linked to depression or to the personality traits predisposing to depression, most famously in the setting of gene-environment interaction \[[@j_bjmg-2018-0010_ref_029], [@j_bjmg-2018-0010_ref_030]\]. Even though some meta-analyses appear to confirm its role in the etiology of MDD, there is poor replication between similarly designed studies \[[@j_bjmg-2018-0010_ref_031]\]. The *PCLO* gene was first identified as a candidate MDD gene in a GWAS study in which no findings of genome-wide significance were detected, but a suggestive result was obtained for the rs2522833 *PCLO* polymorphism \[[@j_bjmg-2018-0010_ref_032]\]. Again, the attempts to replicate these results have not been completely successful. However, some studies have linked the C allele to an increased vulnerability to depression, both directly and through its influence on those personality traits which increase the risk of MDD \[[@j_bjmg-2018-0010_ref_033], [@j_bjmg-2018-0010_ref_034]\].

Our study conducted in Slovene MDD patients found no evidence of a link between the presence of putative high risk alleles in *COMT*, *PCLO* or *SLC6A4* and the likelihood of either having depression or having a family history of depressive disorder. On the contrary, our results for the *PCLO* rs2522833 polymorphism show that homozygosity for the presumed high risk C allele is less common in patients with a positive family history for a depressive disorder compared to those with no family history of depression or compared to the controls. The small number of participants in this study prohibits any definite conclusions to be drawn from these results as there is a possibility that the association we have detected has arisen due to chance. Nevertheless, these findings would appear to suggest that a polymorphism previously associated with both MDD and endophenotypes seen as predisposing factors for depression is not a contributing factor for MDD in families with several affected members. It therefore seems possible that the genetic factors involved in the etiology of depression in families with several affected family members differ from those involved in sporadic cases of depression. Rare variants of great affect would appear to be the most likely candidates, especially in families with a greater number of affected members, a recognizably Mendelian pattern of inheritance, and early disease onset. Such patients would therefore seem more appropriate candidates for next generation sequencing (NGS)-based techniques of investigation rather than SNP genotyping.

The genetic architecture of the most common diseases, including depression, is likely to be complex, with rare cases of clear monogenic inheritance and a somewhat greater number of familial cases associated with oligogenic inheritance. In most patients with common diseases, however, a great number of common risk variants is thought to contribute to the likelihood of developing the disease. Our findings raise an interesting question for those searching for such common variants associated with depression: if the failure of past studies is due to the heterogeneous nature of genetic causes involved in different patients, could excluding patients with similarly affected relatives increase the chance of positive findings in sporadic cases? Although no statistically significant differences were discovered when comparing our patients with no family history of depression to the controls, there was a trend towards a greater S allele frequency for the *SLC6A4* 5-HTTLPR variant and a trend towards a greater C allele frequency and CC homozygosity for the *PCLO* rs2522833 polymorphism in these patients; both variants have also been linked to MDD in the past. This trend was undetectable when all depressed patients were compared to the controls, suggesting that the admixture of familial cases changed the genotype and allele distributions. Our results show that focusing on sporadic cases of depression might provide a more homogenous sample for future association studies. The number of participants included in GWAS would no longer have to be prohibitively large and such studies might stand a better chance of detecting variants with a small contribution to the overall disease risk.

Some of the previous studies which subdivided the participants according to their family history only enquired about first-degree relatives \[[@j_bjmg-2018-0010_ref_028]\]. As there is evidence that the presence of MDD in second-degree relatives can influence the risk of developing depression, we would suggest that one should also enquire about the disease status in second- and perhaps even third-degree relatives \[[@j_bjmg-2018-0010_ref_021]\].

One of the limitations of our study is the small number of participants. The study was therefore underpowered to detect significant associations. Furthermore, as all of the data concerning the family history of our participants was collected by patient recall, some of it was bound to be unreliable and incomplete.

Major depressive disorder is an important health problem worldwide and studying its genetic etiology might one day lead to better diagnostic and treatment options for those affected \[[@j_bjmg-2018-0010_ref_035], [@j_bjmg-2018-0010_ref_036]\]. However, no genetic variants identified so far seem to offer hope of a clinically useful screening test for the near future \[[@j_bjmg-2018-0010_ref_037]\]. As researchers try out different approaches to genetic studies of depression, stratifying patients into subgroups when performing a GWAS becomes increasingly important \[[@j_bjmg-2018-0010_ref_038], 0\]. We would argue that enquiring about the patients' extended family history of this disease could prove a simple and effective way of differentiating patients with different genetic etiologies.

Conclusions {#j_bjmg-2018-0010_s_005}
===========

In our study, no difference in the genotype and allele distributions for the above-mentioned three common polymorphisms was detected when comparing patients with MDD to healthy controls. However, our results seem to indicate that there is a difference in the genetic make-up of MDD patients with a positive family history of depressive disorder compared to sporadic cases. Further studies involving a much greater number of participants and a greater number of tested genetic variants would be necessary to either confirm or refute these findings.
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